Abrocitinib as a novel treatment for lichen sclerosus

Abstract

Ten patients were recruited to evaluate the efficacy and safety of abrocitinib for the treatment of lichen sclerosus (LS). All patients reported rapid control of pruritus at week 2 and achieved Investigator’s Global Assessment 0 or 1 at week 12. This study suggests that the abrocitinib could be an effective and safe treatment option for LS, based on the significant improvements seen in investigator evaluations, patient-reported outcomes and skin imaging findings.